Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Read More
We are working hard to bring novel targeted therapies to children with brain tumors and potentially others who can benefit.
Read More
Read More
Read More
This will close in 5 seconds